- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03215836
Obesity, Metabolic Dysregulation and the Airway Epithelium in Asthmatics
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a cross sectional pilot study comparing specific metabolic pathways in bronchial airway epithelial cells and the nasal epithelium across the following patient groups:
- Obese (Body Mass Index (BMI) ≥ 30) asthmatics without metabolic syndrome,
- Obese asthmatics with metabolic syndrome,
- Obese non-asthmatics, and
- Non - obese (lean > 18 <= 25, Overweight (OW) > 25 - <30) asthmatics.
Participants in these groups will be matched by gender, age and asthma severity. To be enrolled, participants must be non-current smokers and be controlled. After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
Participants without a bronchodilator withhold will be scheduled to undergo a methacholine test. Those that qualify will undergo a bronchoscopy to obtain bronchoalveolar lavage and airway epithelial cells and nasal epithelial brush sampling for gene expression studies. After the procedure is done and post bronchoscopy safety standards are met, participants will be discharged from the inpatient Clinical Translational Research Center (CTRC) recovery area. The research coordinator will call the participant on the night of the procedure and on the next day to document post-procedure clinical stability.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado
-
Contact:
- Asthma Research
- Phone Number: 844-365-0852
- Email: asthmaresearch@ucdenver.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For ALL Groups
- Adequate completion of informed consent process with written documentation
- Male and female patients, ≥ 18 - 65 years old
Smoking history <10 pack years and no smoking in the last year
**Subjects can be included in the study if they are on blood pressure treatment and are on a diet control/exercise only treatment of diabetes.
- Specific to Asthma Groups
i. From all racial/ethnic backgrounds with a diagnosis of asthma based on physician diagnosis for >6 months
- Specific to Metabolic Syndrome Group. Metabolic syndrome diagnosis based on having at least any three of: a. Triglycerides ≥ 150 mg/dl; b. High-density lipoproteins (HDL) cholesterol ≤ 50 mg/dl for women and ≤ 40 mg/dl for men; c Fasting blood glucose ≥ 100 mg/dl; d. Waist circumference > 40 inches males and > 35 inches females); e. Previously diagnosed hypertension or on antihypertensive medication; f. Blood pressure greater than 130/85 on two consecutive measurements.
Specific to Non-Metabolic Syndrome Group a. Baseline pre-bronchodilator forced expiratory volume (FEV1) of 50% or greater of predicted with a 12% or greater bronchodilator (BD) response to 4 puffs of albuterol or PC20 methacholine (16 mg) if no BD response; b. BMI ≥ 30
Metabolic syndrome diagnosis based on having at least any three of:
i. Triglycerides ≥ 150 mg/dl; ii. HDL cholesterol ≤ 50 mg/dl for women and ≤ 40 mg/dl for men; iii. Fasting blood glucose ≥ 100 mg/dl; iv. Waist circumference > 40 inches males and > 35 inches females); v. Previously diagnosed hypertension or on antihypertensive medication; vi. Blood pressure greater than 130/85 on two consecutive measurements.
Specific to Non-Obese Group a. Body Mass Index (BMI) < 30
b. Specific to Non-Asthma Group i. No history of asthma or any other airway diseases; ii. Pulmonary function test within normal limits; iii. BMI ≥ 30.
Exclusion Criteria (all groups):
- Significant or uncontrolled concomitant medical illness (PI discretion) including, but not limited to heart disease, cancer, diabetes (HbAc1 > 6.5), renal disease (creatinine > 2.0) at Visit 0, neurological (brain damage) or psychiatric disorder (diagnosed by a mental health professional of behavioral or mental pattern that may cause suffering or a poor ability to function in life);
- Chronic renal failure (creatinine > 2.0) at screening (associated with higher asymmetric dimethylarginine (ADMA) levels);
- Current statins use (statins lower ADMA levels);
- On diabetic medications;
- Positive pregnancy test;
- Positive urine cotinine and/or urine tetrahydrocannabinol (THC) test;
- Current or recent (within 30 days) investigational treatment or participation in another interventional research study (including non-pharmacologic interventions);
Unable or unlikely to complete study assessments or the study intervention (i.e. bronchoscopy) poses undue risk to patient in the opinion of the investigator.
a. Specific to Asthma Groups i. Respiratory tract infection within the last 4 weeks; ii. Oral or systemic corticosteroids (CS) burst within the last 4 weeks; iii. Asthma-related hospitalization within the last 2 months; iv. Asthma-related ER visit within the previous 4 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Obese Asthmatics
BMI >/= 30 and without metabolic syndrome
|
After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met.
Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
|
Other: Obese Astmatics
BMI >/= 30 and with metabolic syndrome
|
After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met.
Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
|
Other: Obese non-asthmatics
BMI >/= 30
|
After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met.
Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
|
Other: Non - obese asthmatics
BMI: lean > 20; Normal >/= 20 to <25; overweight </= 25 to < 30;
|
After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met.
Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of L-arginine-NO biosynthesis pathways in the airway epithelium in obese and non-asthmatics.
Time Frame: Within 6 months of collection
|
L-arginine-NO biosynthesis pathways will be measured in the airway epithelium of mild to moderate controlled obese and non-obese asthmatics with metabolic syndrome by ELISA and western blot analysis.
|
Within 6 months of collection
|
Measurement of oxidative stress in the airway epithelium in obese and non-asthmatics.
Time Frame: Within 6 months of collection
|
Oxidative stress will be measured in the airway epithelium of mild to moderate controlled obese and non-obese asthmatics without metabolic syndrome by Griess Reaction and western blot analysis.
|
Within 6 months of collection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of mitochondrial density
Time Frame: Within 6 months of collection
|
Mitochondrial density will be measured from cells obtained by one time pulmonary lavage during bronchoscopy.
|
Within 6 months of collection
|
Measurement of mitochondrial structural differences.
Time Frame: Within 6 months of collection
|
Mitochondrial structural differences will be measured from cells obtained by one time pulmonary lavage during bronchoscopy.
|
Within 6 months of collection
|
Patterns of Gene expression found in the nasal epithelium.
Time Frame: Within 6 months of collection
|
Nasal epithelial cells will be obtained by one time nasal brushings and gene expression patterns will be evaluated.
|
Within 6 months of collection
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Fernando Holguin, MD, MPH, University of Colorado Denver, Anschutz Medical Campus
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-2522
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Bronchoscopy and Nasal Epithelium Brush Sampling
-
Washington University School of MedicineActive, not recruitingPregnancy Related | Innate Inflammatory ResponseUnited States
-
Medical University of ViennaRecruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Nasal Polyps | Chronic Rhinosinusitis With Nasal PolypsAustria
-
Royal Brisbane and Women's HospitalCompleted
-
Imperial College Healthcare NHS TrustPulmocide LtdCompletedRespiratory Failure | Bronchiolitis | RSV Infection | Bronchiolitis, ViralUnited Kingdom
-
University of California, Los AngelesMichael E. DeBakey VA Medical Center; Atlanta VA Medical Center; VA Greater Los... and other collaboratorsRecruitingCOVID-19 | Frailty Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Organ Dysfunction Syndrome, MultipleUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
Institut d'Investigació Biomèdica de BellvitgeInstitut Català d'Oncologia; Institut Català de la Salut; Complejo Hospitalario...RecruitingCervical Cancer Screening | HPV-Related Cervical Carcinoma | Self-samplingSpain
-
King's College Hospital NHS TrustKing's College London; Danish Epilepsy CentreRecruitingEpilepsy | Focal Cortical DysplasiaUnited Kingdom
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Teststation Praxis Dr. med BieleckiActive, not recruitingCOVID-19 | Telemedicine | PharynxSwitzerland